Ozempic vs. Wegovy, Mounjaro vs. Zepbound, semaglutide vs. tirzepatide—there are a lot of names and terms to keep straight in the GLP-1 world.

And with Goldman Sachs projecting the obesity treatment market will hit $95 billion by 2030, now may be the time to learn the difference.

So if you’re confused about what’s what and who’s who, never fear: Healthcare Brew has put together a handy guide giving a rundown of the key players.

Semaglutide. Semaglutide is the active ingredient in brand-name drugs Ozempic, Wegovy, and Rybelsus. It’s a single-hormone agent that mimics glucagon-like peptide-1, or GLP-1, according to Chika Anekwe, obesity medicine clinical director at Massachusetts General Hospital’s weight center.

Find the rest of our explainer here.—MA

Now that the Supreme Court officially ruled last week the Trump administration can cut $783 million in research grants as part of its defunding of the National Institutes of Health (NIH) that started in February, universities and hospitals across the country are left scrambling to remain stable.

Healthcare and academic research rely heavily on NIH funding. Fierce Healthcare reported NIH funding drives the economy, bringing in $2.56 for every dollar of spent funding and supporting 400,000+ jobs across the country.

The UMass Chan Medical School laid off or furloughed 209 employees and cut its incoming fall 2025 graduate class by 86% (70 students to 10) due to cuts, according to court documents related to the case.

The American College of Obstetricians also stopped accepting federal funding due to the administration’s anti-DEI push, which it said conflicted with its efforts to reduce maternal health issues.

Still, the White House is set on limiting money across federal agencies, proposing $27 billion in NIH funding—that’s $18 billion less than before—in the Trump administration’s discretionary budget proposal.

Leaders are getting more resourceful, but is it enough?—CM

The Department of Health and Human Services (HHS) and Centers for Medicare and Medicaid Services (CMS) are forming a new committee meant to advise the agencies on policies to “improve how care is financed and delivered” under federal health insurers.

Dubbed the Healthcare Advisory Committee, the group is intended to help HHS and CMS meet goals set under the Trump administration’s Make America Healthy Again agenda. This includes chronic disease prevention, reducing “unnecessary red tape” within federal insurance programs, making Medicare Advantage more sustainable, and identifying “structural opportunities to improve quality for the most vulnerable in the Medicaid program,” according to an Aug. 21 agency press release.

Ge Bai, a professor of health policy and management at Johns Hopkins Bloomberg School of Public Health, told Healthcare Brew that deregulation will likely be a priority.

“To me, it’s probably a signal of some kind of a significant change in direction as compared to previous administrations,” Bai said.

Here’s what the new committee plans to tackle.—MA

Real jobs, shared through real communities. CollabWORK brings opportunities directly to Healthcare Brew readers—no mass postings, no clutter, just roles worth seeing. Click here to view the full job board.

• Chief Physician Executive at an academic medical center (in person)
• Director of Nursing at La Villa Grande Care Center (in person)
• Director of Nursing - RN - Long Term Care at Good Samaritan (in person)
• Chief Executive Officer (CEO), Hospital at a home & facility-based healthcare service (in person)
• Executive Director, Clinical Supply Chain at a biopharmaceutical company (in person)